Immuno Vaccine Inc (IMMVF) 0.7230 $IMMVF
Immunovaccine Adds Broad Business Operations and Capital Raising Expertise to Board of Directors with New Appointments
Marketwire - Fri Sep 26, 7:06AM CDT
Immunovaccine Inc. ("Immunovaccine" or "IMV" or "the Company"
(TSX VENTURE: IMV), a clinical stage vaccine and immunotherapy company, has elected Wade K. Dawe and Alfred A. Smithers to its board of directors. The appointments are effective immediately.
Global Ebola and Marburg Infections Therapeutics Pipeline Report 2014 - 10 Companies & 12 Drug Profiles
M2 - Tue Sep 09, 9:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gjrkc2/ebola_and_marburg) has announced the addition of the "Ebola and Marburg Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ebola and Marburg Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ebola and Marburg Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Crucell N.V. - NanoViricides, Inc. - AlphaVax, Inc. - Immunovaccine, Inc. - Integrated BioTherapeutics, Inc. - Profectus BioSciences, Inc. - Mapp Biopharmaceutical, Inc. Drug Profiles - Vaccine for Multivalent Filovirus - Ebola Vaccine Marburg Vaccine - Vaccine For Filovirus - Ebola/Marburg Program - Ebola And Marburg Vaccine - Monoclonal Antibody for Marburg Virus - Polyvalent DNA Vaccine for Ebola and Marburg Filoviruses - MVA-BN-Filoviruses Vaccine - rVSV-Vectored Vaccines - Subunit Vaccine for Multifiloviruses - Monoclonal Antibodies to Inhibit Glycoprotein for Marburg Virus Infection - Monoclonal Antibodies for Ebola and Marburg Infections For more information visit http://www.researchandmarkets.com/research/gj...nd_marburg
IIROC Trade Resumption - Immunovaccine Inc.
Newsfile Corp - Tue Aug 26, 1:20PM CDT
Trading resumes in:
IIROC Trade Halt - Immunovaccine Inc.
Newsfile Corp - Tue Aug 26, 7:08AM CDT
The following issues have been halted by IIROC:
Ebola Vaccine Using Immunovaccine's DepoVax Proves Highly Efficacious in Non-Human Primate Study
Marketwire - Mon Aug 25, 9:31AM CDT
Immunovaccine Inc. ("Immunovaccine" (TSX VENTURE: IMV), a clinical stage vaccine company, today announced positive results for a vaccine formulated in its DepoVax(TM) technology in an Ebola virus challenge study performed by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). In a preliminary study using cynomolgus monkeys, which are particularly sensitive to the Ebola virus, all vaccinated subjects survived exposure to a lethal dose of the wild type Zaire strain of the virus. All unvaccinated control animals succumbed to the disease.
Immunovaccine Announces Financial Results for Quarter Ended June 30, 2014
Marketwire - Fri Aug 15, 7:06AM CDT
Immunovaccine Inc. ("Immunovaccine" or "IMV" (TSX VENTURE: IMV), a clinical stage vaccine company, today released its financial and operational results for the quarter ended June 30, 2014.
Immunovaccine to Present at Ninth Annual Immunotherapies and Vaccines Summit (ImVacS) Conference
Marketwire - Tue Aug 12, 7:06AM CDT
Immunovaccine Inc. ("Immunovaccine" or "IMV" (TSX VENTURE: IMV), a clinical stage vaccine company, announced today that Marc Mansour, Ph.D., the Company's chief executive officer, will make a presentation at the Ninth Annual Immunotherapies and Vaccines Summit (ImVacS). In addition to his presentation, Dr. Mansour will also serve as chairperson of the conference's "Clinical Updates of Combination Immunotherapies" session. The conference will take place on August 11-14, 2014 at the Marriott Long Wharf Hotel in Boston, MA.
Immunovaccine and Pfenex Report Positive Results from Single Dose Anthrax Vaccine Studies
Marketwire - Tue Apr 01, 7:06AM CDT
Immunovaccine Inc. ("Immunovaccine" (TSX VENTURE: IMV) and Pfenex Inc. ("Pfenex" today announced positive results from anthrax challenge studies in rabbits using Pfenex's mutant recombinant Protective Antigen (mrPA) formulated with Immunovaccine's DepoVax(TM) delivery system. The studies showed that animals administered a vaccine containing mrPA formulated in DepoVax were protected against a lethal anthrax challenge at a range of antigen doses.
Immunovaccine Announces 2013 Year-End Results
Marketwire - Mon Mar 17, 7:06AM CDT
Immunovaccine Inc. (TSX VENTURE: IMV), a clinical stage vaccine company, today announced its financial and operational results for the year ended December 31, 2013.
MediMabs Announces the Appointment of Two New Members of the Board of Directors
Marketwire - Thu Feb 20, 10:52AM CST
Ms. Sarita Benchimol, the President and Chief Executive Officer of MediMabs Inc., is pleased to announce the election to the MediMabs Board of Directors of Dr. Randal Chase PhD and Mr. R Martin Wong CPA, CA. Both individuals were elected at the company's shareholder meeting and will be joining the existing board of directors, which includes Dr. Phil Gold CC, OQ, MD, PhD, FRSCopyright, FRCPCopyright, MACP, Dr. Claudio Cuello OC, MD, DSc, FRSCopyright, Mr. Miguel Madanes Eng., and Ms. Sarita Benchimol MSc.
Ebola and Marburg Infections - Pipeline Review, H2 2013 Report
M2 - Tue Feb 04, 2:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/bv7mx8/ebola_and_marburg) has announced the addition of the "Ebola and Marburg Infections - Pipeline Review, H2 2013" report to their offering. 'Ebola and Marburg Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ebola and Marburg Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ebola and Marburg Infections. Scope - A snapshot of the global therapeutic scenario for Ebola and Marburg Infections. - A review of the Ebola and Marburg Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ebola and Marburg Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Inovio Pharmaceuticals, Inc. Bavarian Nordic A/S Crucell N.V. NanoViricides, Inc. SIGA Technologies, Inc. Functional Genetics, Inc. Okairos AG AlphaVax, Inc. Immunovaccine, Inc. Mapp Biopharmaceutical, Inc. For more information visit http://www.researchandmarkets.com/research/bv...nd_marburg About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Immunovaccine Adds Broad Business Operations and Capital Raising Expertise to Board of Directors with New Appointments
Marketwire - Fri Sep 26, 7:06AM CDT
Immunovaccine Inc. ("Immunovaccine" or "IMV" or "the Company"
(TSX VENTURE: IMV), a clinical stage vaccine and immunotherapy company, has elected Wade K. Dawe and Alfred A. Smithers to its board of directors. The appointments are effective immediately. Global Ebola and Marburg Infections Therapeutics Pipeline Report 2014 - 10 Companies & 12 Drug Profiles
M2 - Tue Sep 09, 9:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gjrkc2/ebola_and_marburg) has announced the addition of the "Ebola and Marburg Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ebola and Marburg Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ebola and Marburg Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Crucell N.V. - NanoViricides, Inc. - AlphaVax, Inc. - Immunovaccine, Inc. - Integrated BioTherapeutics, Inc. - Profectus BioSciences, Inc. - Mapp Biopharmaceutical, Inc. Drug Profiles - Vaccine for Multivalent Filovirus - Ebola Vaccine Marburg Vaccine - Vaccine For Filovirus - Ebola/Marburg Program - Ebola And Marburg Vaccine - Monoclonal Antibody for Marburg Virus - Polyvalent DNA Vaccine for Ebola and Marburg Filoviruses - MVA-BN-Filoviruses Vaccine - rVSV-Vectored Vaccines - Subunit Vaccine for Multifiloviruses - Monoclonal Antibodies to Inhibit Glycoprotein for Marburg Virus Infection - Monoclonal Antibodies for Ebola and Marburg Infections For more information visit http://www.researchandmarkets.com/research/gj...nd_marburg
IIROC Trade Resumption - Immunovaccine Inc.
Newsfile Corp - Tue Aug 26, 1:20PM CDT
Trading resumes in:
IIROC Trade Halt - Immunovaccine Inc.
Newsfile Corp - Tue Aug 26, 7:08AM CDT
The following issues have been halted by IIROC:
Ebola Vaccine Using Immunovaccine's DepoVax Proves Highly Efficacious in Non-Human Primate Study
Marketwire - Mon Aug 25, 9:31AM CDT
Immunovaccine Inc. ("Immunovaccine"
(TSX VENTURE: IMV), a clinical stage vaccine company, today announced positive results for a vaccine formulated in its DepoVax(TM) technology in an Ebola virus challenge study performed by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). In a preliminary study using cynomolgus monkeys, which are particularly sensitive to the Ebola virus, all vaccinated subjects survived exposure to a lethal dose of the wild type Zaire strain of the virus. All unvaccinated control animals succumbed to the disease. Immunovaccine Announces Financial Results for Quarter Ended June 30, 2014
Marketwire - Fri Aug 15, 7:06AM CDT
Immunovaccine Inc. ("Immunovaccine" or "IMV"
(TSX VENTURE: IMV), a clinical stage vaccine company, today released its financial and operational results for the quarter ended June 30, 2014. Immunovaccine to Present at Ninth Annual Immunotherapies and Vaccines Summit (ImVacS) Conference
Marketwire - Tue Aug 12, 7:06AM CDT
Immunovaccine Inc. ("Immunovaccine" or "IMV"
(TSX VENTURE: IMV), a clinical stage vaccine company, announced today that Marc Mansour, Ph.D., the Company's chief executive officer, will make a presentation at the Ninth Annual Immunotherapies and Vaccines Summit (ImVacS). In addition to his presentation, Dr. Mansour will also serve as chairperson of the conference's "Clinical Updates of Combination Immunotherapies" session. The conference will take place on August 11-14, 2014 at the Marriott Long Wharf Hotel in Boston, MA. Immunovaccine and Pfenex Report Positive Results from Single Dose Anthrax Vaccine Studies
Marketwire - Tue Apr 01, 7:06AM CDT
Immunovaccine Inc. ("Immunovaccine"
(TSX VENTURE: IMV) and Pfenex Inc. ("Pfenex" today announced positive results from anthrax challenge studies in rabbits using Pfenex's mutant recombinant Protective Antigen (mrPA) formulated with Immunovaccine's DepoVax(TM) delivery system. The studies showed that animals administered a vaccine containing mrPA formulated in DepoVax were protected against a lethal anthrax challenge at a range of antigen doses. Immunovaccine Announces 2013 Year-End Results
Marketwire - Mon Mar 17, 7:06AM CDT
Immunovaccine Inc. (TSX VENTURE: IMV), a clinical stage vaccine company, today announced its financial and operational results for the year ended December 31, 2013.
MediMabs Announces the Appointment of Two New Members of the Board of Directors
Marketwire - Thu Feb 20, 10:52AM CST
Ms. Sarita Benchimol, the President and Chief Executive Officer of MediMabs Inc., is pleased to announce the election to the MediMabs Board of Directors of Dr. Randal Chase PhD and Mr. R Martin Wong CPA, CA. Both individuals were elected at the company's shareholder meeting and will be joining the existing board of directors, which includes Dr. Phil Gold CC, OQ, MD, PhD, FRSCopyright, FRCPCopyright, MACP, Dr. Claudio Cuello OC, MD, DSc, FRSCopyright, Mr. Miguel Madanes Eng., and Ms. Sarita Benchimol MSc.
Ebola and Marburg Infections - Pipeline Review, H2 2013 Report
M2 - Tue Feb 04, 2:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/bv7mx8/ebola_and_marburg) has announced the addition of the "Ebola and Marburg Infections - Pipeline Review, H2 2013" report to their offering. 'Ebola and Marburg Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ebola and Marburg Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ebola and Marburg Infections. Scope - A snapshot of the global therapeutic scenario for Ebola and Marburg Infections. - A review of the Ebola and Marburg Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ebola and Marburg Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Inovio Pharmaceuticals, Inc. Bavarian Nordic A/S Crucell N.V. NanoViricides, Inc. SIGA Technologies, Inc. Functional Genetics, Inc. Okairos AG AlphaVax, Inc. Immunovaccine, Inc. Mapp Biopharmaceutical, Inc. For more information visit http://www.researchandmarkets.com/research/bv...nd_marburg About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
